MSF: TB test price reduction by Cepheid and Danaher is an important step in the right direction
September 19, 2023Cepheid and its parent company Danaher announced today that they are reducing the price of the Xpert MTB/RIF test for TB by 20 percent in high-TB-burden countries from US$9.98 to $7.97 per test. This reduction is a significant step, considering the...
Read more
Ahead of UN TB High-Level Meeting, US corporations J&J and Cepheid must pledge access to lifesaving TB medicines and tests for everyone in need
September 12, 2023TB is curable but remains the world’s leading infectious disease killer 12 September 2023, Geneva/New York – Next week, world leaders meet for the second-ever global tuberculosis (TB) High-Level Meeting at the United Nations (UN) in New York, to endorse...
Read more
MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics
July 18, 2023MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics. Recent deal offering controlled generics access in limited countries does not go...
Read more
MSF applauds Indian Patent Office’s rejection of Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug
March 23, 2023Mumbai, 23 March 2023 – Today, the 2019 patent challenge by two tuberculosis (TB) survivors, Nandita Venkatesan and Phumeza Tisile, was successful: the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly...
Read more
Urgent need to improve access to TB testing to support rollout of better, safer, shorter treatment for drug-resistant TB
March 22, 2023Delhi, 22 March 2023 - Médecins Sans Frontières/Doctors Without Borders (MSF) called on governments and donors today to speed up access to new, shorter, safer and more effective treatments* for drug-resistant tuberculosis (DR-TB), as well as the diagnostic tests needed...
Read more
Afghanistan: The MSF hospital in Kandahar provides hope for people with TB
December 8, 2022Jawahira was referred to the Médecins Sans Frontières (MSF) tuberculosis (TB) hospital in Kandahar earlier this year from a clinic in Daikundi, central Afghanistan. “I used to visit private clinics, but instead of giving me TB medication, they usually just...
Read more
Between life and living: Patients with drug-resistant tuberculosis (DR-TB) share stories of strength, support and suffering
December 2, 2022India has the highest burden of both tuberculosis (TB) and multi-drug resistant tuberculosis (MDR-TB) based on estimates in the WHO Global TB Report 2022. The country accounts for 28 percent of the global TB burden. In its clinic in Mumbai, MSF...
Read more
Global TB Report 2022: MSF calls for scale up of shorter and safer DR-TB treatments to help save more lives
October 28, 2022The World Health Organization (WHO) released today the 2022 edition of its Global Tuberculosis (TB) Report, featuring data on the TB response and trends in 215 countries and areas. Among the alarming trends from 2021, there is an increase in the estimated...
Read more
Tuberculosis: EndTB clinical trial for multidrug-resistant TB completes enrolment
October 18, 2021BOSTON/PARIS — Hundreds of patient volunteers from four continents have enrolled in a trial that aims to find safer, shorter, and effective treatments for multidrug-resistant tuberculosis (MDR-TB), an airborne, infectious disease that has grown resistant to standard medications. A group of scientists and...
Read more
Access to Medicines: Lifesaving TB medicines still out of reach for children in high-burden countries
September 3, 2021Geneva - The World Health Organization (WHO) recently released new rapid guidance recommending that children of all ages with drug-resistant tuberculosis (DR-TB) have access to all-oral treatment using the drugs bedaquiline and/or delamanid. However, adopting these new recommendations in high TB...
Read more
Tuberculosis: Trial of multidrug-resistant TB treatment ends enrolment early after independent board indicates new regimen is superior
March 24, 2021LONDON - A trial aiming to find a better treatment for multidrug-resistant tuberculosis (MDR-TB) has stopped enrolling patients early after its independent data safety and monitoring board indicated that the regimen being studied is superior to current care, and more...
Read more
endTB trial: First patient enrolls for clinical trials of novel, short and all-oral regimens for multidrug-resistant tuberculosis in India
October 22, 2020Pune, India: Doctors Without Borders/ Médecins Sans Frontières (MSF) in collaboration with Indian Council for Medical Research (ICMR)- National AIDS Research Institute (NARI) and Department of Health Service, Government of Maharashtra is initiating two major clinical trials that aim at generating clinical evidence...
Read more
